Castleark Management LLC boosted its position in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 42.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 102,930 shares of the company's stock after acquiring an additional 30,800 shares during the quarter. Castleark Management LLC owned 0.12% of HealthEquity worth $9,876,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of HealthEquity by 11.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 366,753 shares of the company's stock valued at $35,190,000 after buying an additional 37,276 shares during the last quarter. Shay Capital LLC bought a new position in HealthEquity during the fourth quarter valued at $547,000. Royal Bank of Canada grew its position in HealthEquity by 10.6% in the fourth quarter. Royal Bank of Canada now owns 433,190 shares of the company's stock worth $41,563,000 after acquiring an additional 41,434 shares in the last quarter. ProShare Advisors LLC increased its position in shares of HealthEquity by 42.8% during the 4th quarter. ProShare Advisors LLC now owns 28,253 shares of the company's stock valued at $2,711,000 after purchasing an additional 8,462 shares during the last quarter. Finally, Quantinno Capital Management LP purchased a new stake in shares of HealthEquity in the fourth quarter valued at $305,000. Institutional investors own 99.55% of the company's stock.
HealthEquity Stock Down 1.1%
HQY traded down $1.07 on Monday, hitting $99.01. The company had a trading volume of 908,113 shares, compared to its average volume of 808,012. The stock has a market capitalization of $8.56 billion, a price-to-earnings ratio of 90.83, a P/E/G ratio of 1.60 and a beta of 0.45. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20. The stock has a fifty day moving average price of $88.03 and a 200-day moving average price of $97.40. HealthEquity, Inc. has a 12-month low of $65.01 and a 12-month high of $115.59.
Insider Transactions at HealthEquity
In related news, Director Robert W. Selander sold 5,750 shares of the company's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $77.65, for a total transaction of $446,487.50. Following the transaction, the director now directly owns 84,969 shares of the company's stock, valued at $6,597,842.85. This represents a 6.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Michael Henry Fiore sold 8,881 shares of the firm's stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $78.26, for a total value of $695,027.06. Following the completion of the sale, the executive vice president now directly owns 56,655 shares of the company's stock, valued at approximately $4,433,820.30. This represents a 13.55% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.50% of the company's stock.
Analyst Ratings Changes
Several analysts have recently weighed in on HQY shares. Royal Bank of Canada began coverage on HealthEquity in a research report on Thursday. They set an "outperform" rating and a $112.00 target price for the company. Raymond James raised shares of HealthEquity from an "outperform" rating to a "strong-buy" rating and lowered their price objective for the company from $120.00 to $115.00 in a research report on Tuesday, March 25th. Wells Fargo & Company lifted their price target on shares of HealthEquity from $110.00 to $125.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Barrington Research reaffirmed an "outperform" rating and set a $112.00 target price on shares of HealthEquity in a research report on Friday, April 11th. Finally, The Goldman Sachs Group lowered their target price on HealthEquity from $107.00 to $94.00 and set a "neutral" rating for the company in a report on Thursday, March 27th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, HealthEquity has a consensus rating of "Buy" and a consensus price target of $112.33.
Check Out Our Latest Report on HealthEquity
HealthEquity Company Profile
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
See Also
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
